HEALTHPOINT Canada, a division of HEALTHPOINT Ltd., , began marketing COOK Biotech Incorporated's patented wound matrix product, Oasis, in Canada this month through a distribution partnership with Trudell Medical Marketing Limited. More
Patents were recently granted in 12 new countries for SULIDIN® LPS® (Topical Nimesulide Gel). Licensees are sought in these and other territories worldwide. More
Zambon and APR have recently signed a Strategic Alliance and License Agreement for the further development and marketing of innovative patented consumer oriented products in patch form. More
Two new studies on the Efficacy, Tolerability and Safety of Kortos® HC cream and Kortos® HC Suppository have been carried out, found to be highly efficacous and well tolerated with no clinically relevant systemic or local side/adverse effects More
Zambon and APR Applied Pharma Research S.A. have signed an international license agreement for the further development of innovative patented products in matrix patch form More
Healthpoint Ltd. has announced that the United States Patent and Trademark Office has granted Healthpoint a Notice of Allowance on its patent application for the ointment vehicle that is the basis for Healthpoint's Xenaderm(tm). More
Rapid In-vitro Percutaneous Penetration Profile of Sulidin® 1% Nimesulide LPS topical gel to be presented at the 8'th International Conference on Percutaneous Penetration. More
Dr Duncan Aust joins one of the fastest growing R & D groups in the industry: Dedicated to dermatology, skin diseases and wound and tissue management. More
Displaying 1..10 of 19 -
per page
Next page
Order by